SCHEMBL25367134

SCHEMBL25367134

CC(=O)N1C(=S)NC(=O)C1Cc1cccc(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.41
CACNA1F O60840 1/20 0.40
CACNA1D Q01668 1/20 0.40
CACNA1S Q13698 1/20 0.40
CACNA1C Q13936 1/20 0.40
TP53 P04637 1/20 0.39
MDM2 Q00987 1/20 0.39
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
HSD17B2 P37059 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 1/20 0.37
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
GLA P06280 1/20 0.36
HSD11B1 P28845 1/20 0.36
TSHR P16473 1/20 0.36
FSHR P23945 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25367130 1.00 KMT2A (0.41) KMT2ACACNA1FCACNA1DCACNA1SCACNA1C
SCHEMBL25363327 0.86 BRD4 (0.42) KMT2AALDH1A1SMN1; SMN2MEN1KIF11
SCHEMBL25366343 0.85 NPC1 (0.38) KMT2AALDH1A1MAPTMEN1MAOB
SCHEMBL25367152 0.85 NPSR1 (0.46) KMT2AALDH1A1LMNAMAPTNPSR1
SCHEMBL25366861 0.78 ALDH1A1 (0.38) KMT2AALDH1A1LMNAMAPTNPSR1
SCHEMBL25368673 0.78 HPGD (0.43) KMT2ACACNA1FCACNA1DCACNA1SCACNA1C
SCHEMBL25367741 0.77 MEN1 (0.42) KMT2AALDH1A1LMNAMAPTNPSR1
SCHEMBL25366122 0.76 ALDH1A1 (0.43) KMT2AALDH1A1LMNASMN1; SMN2MEN1
SCHEMBL25366772 0.75 ALDH1A1 (0.41) KMT2AALDH1A1LMNANPSR1SMN1; SMN2
SCHEMBL25366766 0.75 ALDH1A1 (0.41) KMT2AALDH1A1LMNANPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS ERMIUM THERAPEUTICS (FR) 2024-01-18 US disclosed
CN-116568675-A Cyclic isothiourea derivatives as CXCR4 modulators 埃尔米乌治疗公司 2023-08-08 CN disclosed
EP-4217353-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS Ermium Therapeutics (FR) 2023-08-02 EP disclosed
WO-2022064075-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS ERMIUM THERAPEUTICS (FR) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018125-A1 CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS CXCR4, CXCR1, CXCL12 KMT2A 4150/4885CACNA1F 3994/4885CACNA1D 4044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.